Achieving virological control in pan-resistant HIV-1 infection: A case series

Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States

(2020) Lucia R.I. Millham et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Simplification to high-genetic-barrier 2-drug regimens in People Living with HIV harboring four-class resistance enrolled in the PRESTIGIO Registry

(2020) Diana Canetti et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

(2020) Michael Kozal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Burden of disease in PLWH harboring a multidrug resistant virus: data from PRESTIGIO Registry

(2020) Laura Galli et al.   Open Forum Infectious Diseases

Brief Report

(2019) Camilla Muccini et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

(2018) Huldrych F Günthard et al.   CLINICAL INFECTIOUS DISEASES

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment

(2018) Daniele Armenia et al.   JOURNAL OF CLINICAL VIROLOGY

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

(2018) Brinda Emu et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study

(2017) Charlotte Charpentier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Global HIV Antiretroviral Drug Resistance

(2017) Catherine Godfrey et al.   JOURNAL OF INFECTIOUS DISEASES

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

(2017) Laura Ciaffi et al.   Lancet HIV

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe

(2016) A Judd et al.   HIV MEDICINE

Complexity and Dynamics of HIV-1 Chemokine Receptor Usage in a Multidrug-Resistant Adolescent

(2014) Mariangela Cavarelli et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

(2011) J. Toma et al.   JOURNAL OF VIROLOGY

Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure

(2009) Francesca Cossarini et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

(2008) J. M. Jacobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine

(2008) R. Paredes et al.   JOURNAL OF VIROLOGY